Why the study?
Many cancer therapies carry an associated risk of cardiotoxicity, necessitating early detection and surveillance before irreversible complications develop.
Cardiovascular magnetic resonance imaging is a valuable non-invasive tool for the early detection and management of cancer therapy-induced cardiotoxicity.
CMR may refine cardiotoxicity surveillance in cancer patients; leaves open its guideline integration pending prospective outcome trials.
Contemporary cancer therapy has resulted in significant survival gains for patients. However, many current and emerging cancer therapies have an associated risk of cardiotoxicity, either acutely or later in life. Regular cardiac screening and surveillance is recommended for patients undergoing treatment for cancer, with emphasis on the early detection of cardiotoxicity before irreversible complications develop. Cardiovascular magnetic resonance imaging is able to accurately assess cardiac structure, function, and perform advanced myocardial tissue characterisation, including perfusion, features which may facilitate the diagnosis and management of cardiotoxicity in cancer survivors. This review outlines the current standards for the diagnosis and screening of cardiotoxicity, with particular focus on current and future applications of cardiovascular magnetic resonance imaging.
No takes yet. Share an insight, caveat, or question.
Burrage et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: